Sign in or create an account to add this stock to your watchlist.
About vTv Therapeutics (NASDAQ:VTVT)
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300
Debt
Debt-to-Equity Ratio-0.09
Current Ratio0.35
Quick Ratio0.35
Price-To-Earnings
Trailing P/E Ratio-0.99
Forward P/E Ratio-1.39
P/E GrowthN/A
Sales & Book Value
Annual Sales$290,000.00
Price / Sales187.87
Cash FlowN/A
Price / CashN/A
Book Value($4.53) per share
Price / Book-0.37
Profitability
EPS (Most Recent Fiscal Year)($1.67)
Net Income$-16,140,000.00
Net Margins-639.83%
Return on EquityN/A
Return on Assets-58.08%
Miscellaneous
Employees56
Outstanding Shares32,820,000
vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions
What is vTv Therapeutics' stock symbol?
vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
How were vTv Therapeutics' earnings last quarter?
vTv Therapeutics Inc (NASDAQ:VTVT) issued its quarterly earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. The biotechnology company earned $2.06 million during the quarter, compared to analysts' expectations of $3.14 million. View vTv Therapeutics' Earnings History.
When is vTv Therapeutics' next earnings date?
What price target have analysts set for VTVT?
8 brokerages have issued 1 year price targets for vTv Therapeutics' shares. Their predictions range from $4.00 to $28.00. On average, they anticipate vTv Therapeutics' stock price to reach $14.7143 in the next year. View Analyst Ratings for vTv Therapeutics.
Are investors shorting vTv Therapeutics?
vTv Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totalling 977,984 shares, a drop of 32.3% from the April 30th total of 1,444,136 shares. Based on an average daily volume of 1,462,831 shares, the days-to-cover ratio is currently 0.7 days. Currently, 14.0% of the shares of the stock are short sold.
Who are some of vTv Therapeutics' key competitors?
Some companies that are related to vTv Therapeutics include Chimerix (CMRX), Aeglea Bio Therapeutics (AGLE), Immune Design (IMDZ), VERONA PHARMA P/S (VRNA), Xoma (XOMA), Menlo Therapeutics (MNLO), Neos Therapeutics (NEOS), Mustang Bio (MBIO), NewLink Genetics (NLNK), Kamada (KMDA), POXEL (PXXLF), Ra Pharmaceuticals (RARX), Calithera Biosciences (CALA), ProQR Therapeutics (PRQR) and VBI Vaccines (VBIV).
Who are vTv Therapeutics' key executives?
vTv Therapeutics' management team includes the folowing people:
- Mr. Jeffrey B. Kindler, Exec. Chairman (Age 62)
- Mr. Stephen L. Holcombe, Pres & CEO (Age 61)
- Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 60)
- Dr. Larry Douglas Altstiel, Exec. VP & Chief Medical Officer (Age 68)
- Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
When did vTv Therapeutics IPO?
(VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
Has vTv Therapeutics been receiving favorable news coverage?
Press coverage about VTVT stock has trended somewhat negative recently, Accern reports. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. vTv Therapeutics earned a media sentiment score of -0.02 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.85 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are vTv Therapeutics' major shareholders?
vTv Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (1.00%), C WorldWide Group Holding A S (0.30%) and Millennium Management LLC (0.29%). Company insiders that own vTv Therapeutics stock include Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.
Which major investors are buying vTv Therapeutics stock?
VTVT stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., C WorldWide Group Holding A S and Millennium Management LLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.
How do I buy shares of vTv Therapeutics?
Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is vTv Therapeutics' stock price today?
One share of VTVT stock can currently be purchased for approximately $1.66.
How big of a company is vTv Therapeutics?
vTv Therapeutics has a market capitalization of $55.47 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe.
How can I contact vTv Therapeutics?
vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PARKWAY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]
MarketBeat Community Rating for vTv Therapeutics (VTVT)
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
vTv Therapeutics (NASDAQ:VTVT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for vTv Therapeutics in the last 12 months. Their average twelve-month price target is $14.7143, suggesting that the stock has a possible upside of 786.40%. The high price target for VTVT is $28.00 and the low price target for VTVT is $4.00. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.25 | 2.25 | 2.83 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $14.7143 | $14.7143 | $18.40 | $16.00 |
| Price Target Upside: | 786.40% upside | 1,465.35% upside | 172.19% upside | 173.04% upside |
vTv Therapeutics (NASDAQ:VTVT) Consensus Price Target History
vTv Therapeutics (NASDAQ:VTVT) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
vTv Therapeutics (NASDAQ:VTVT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
vTv Therapeutics (NASDAQ VTVT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 15.04%
vTv Therapeutics (NASDAQ VTVT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/26/2017 | Ronald O Perelman | Major Shareholder | Buy | 50,000 | $4.03 | $201,500.00 | |  |
| 12/7/2017 | Paul G Savas | Director | Buy | 15,000 | $4.56 | $68,400.00 | 81,781 | |
| 8/22/2017 | Ronald O Perelman | Major Shareholder | Buy | 20,000 | $4.57 | $91,400.00 | | |
| 8/16/2017 | Ronald O Perelman | Major Shareholder | Buy | 10,000 | $4.97 | $49,700.00 | | |
| 8/15/2017 | Ronald O Perelman | Major Shareholder | Buy | 50,000 | $4.72 | $236,000.00 | | |
| 8/11/2017 | Ronald O Perelman | Major Shareholder | Buy | 85,000 | $4.13 | $351,050.00 | | |
| 5/15/2017 | Paul G Savas | Director | Buy | 3,000 | $5.18 | $15,540.00 | 69,881 | |
| 3/31/2017 | Paul G Savas | Director | Buy | 10,000 | $6.50 | $65,000.00 | 66,435 | |
| 5/27/2016 | Paul G Savas | Director | Buy | 6,000 | $5.67 | $34,020.00 | 58,781 | |
| 5/24/2016 | Paul G Savas | Director | Buy | 1,259 | $5.26 | $6,622.34 | 52,526 | |
| 4/8/2016 | Ronald O Perelman | Major Shareholder | Buy | 10,000 | $4.99 | $49,900.00 | | |
| 4/5/2016 | Ronald O Perelman | Major Shareholder | Buy | 400,000 | $5.20 | $2,080,000.00 | | |
| 3/28/2016 | Paul G Savas | Director | Buy | 10,000 | $5.35 | $53,500.00 | 46,522 | |
| 3/24/2016 | Ronald O Perelman | Major Shareholder | Buy | 10,000 | $5.64 | $56,400.00 | | |
| 3/7/2016 | Paul G Savas | Director | Buy | 15,000 | $5.82 | $87,300.00 | 30,000 | |
| 2/12/2016 | Ronald O Perelman | Major Shareholder | Buy | 10,000 | $5.83 | $58,300.00 | | |
| 2/5/2016 | Ronald O Perelman | Major Shareholder | Buy | 10,000 | $6.43 | $64,300.00 | | |
| 2/4/2016 | Ronald O Perelman | Major Shareholder | Buy | 20,000 | $6.05 | $121,000.00 | | |
| 1/13/2016 | Ronald O Perelman | Major Shareholder | Buy | 15,000 | $6.41 | $96,150.00 | | |
| 12/18/2015 | Ronald O Perelman | Major Shareholder | Buy | 15,000 | $6.40 | $96,000.00 | | |
| 12/15/2015 | Noel Joseph Spiegel | Director | Buy | 5,710 | $6.20 | $35,402.00 | 6,000 | |
| 10/2/2015 | Ronald O Perelman | Major Shareholder | Buy | 30,000 | $6.26 | $187,800.00 | | |
| 9/28/2015 | Ronald O Perelman | Major Shareholder | Buy | 40,000 | $6.04 | $241,600.00 | | |
| 9/25/2015 | Paul G Savas | Director | Buy | 5,000 | $6.62 | $33,100.00 | 20,000 | |
| 9/22/2015 | Ronald O Perelman | Major Shareholder | Buy | 24,000 | $6.82 | $163,680.00 | | |
(Data available from 1/1/2013 forward)
vTv Therapeutics (NASDAQ VTVT) News Headlines
| Source: |
|
vTv Therapeutics (NASDAQ:VTVT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
vTv Therapeutics (NASDAQ:VTVT) Income Statement, Balance Sheet and Cash Flow Statement
vTv Therapeutics (NASDAQ VTVT) Stock Chart for Saturday, May, 26, 2018
Loading chart…
